Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd (NQ: TLSA )

0.6599 -0.0109 (-1.62%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,533
Open 0.6700
Bid (Size) 0.6250 (1)
Ask (Size) 0.6597 (46)
Prev. Close 0.6708
Today's Range 0.6538 - 0.7079
52wk Range 0.5005 - 1.393
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) has taken a major step towards addressing Secondary Progressive Multiple Sclerosis (SPMS) by initiating Phase 2a clinical trials for its intranasal foralumab... 
Via Benzinga
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Performance

YTD
+13.78%
+13.78%
1 Month
-9.23%
-9.23%
3 Month
-4.29%
-4.29%
6 Month
-34.99%
-34.99%
1 Year
-15.40%
-15.40%

More News

Read More
Cathie Wood Dumps 170,000 Tesla Shares This Week As TSLA Falls Harder Than The S&P 500
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Tesla Cybertruck To Be Used For Oracle's Next-Gen Police Car
Via Benzinga
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light
Via Benzinga
Exposures Product Safety
Tiziana Life Sciences' Alzheimer's treatment validated in new study
Via News Direct
Tiziana Life Sciences' Alzheimer's treatment validated in new study
Via TheNewswire.com
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Via Benzinga
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision
Via Benzinga
Exposures Product Safety
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Tiziana Life Sciences Stock (TLSA) Is Climbing
Via Benzinga
Exposures Product Safety
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
Via News Direct
Exposures Product Safety
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
Via TheNewswire.com
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Via News Direct
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Via Benzinga
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
Via News Direct
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.